Clearside Biomedical announces plans for ODYSSEY phase 2b trial of CLS-AX

Clearside Biomedical, announced today plans for ODYSSEY, a randomized, double-masked, parallel-group, active-controlled, multi-center Phase 2b clinical trial of CLS-AX using suprachoroidal delivery in neovascular age-related macular degeneration. The Company plans to open the trial for enrollment this quarter and expects topline results in Q3 2024. George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer, commented, "We are excited to advance our CLS-AX program, building on the positive data from our OASIS Phase 1/2a trial, which showed that CLS-AX was well tolerated and demonstrated an excellent safety profile and promising data up to 6 months durability. We believe CLS-AX has the potential to reduce treatment burden in patients with wet AMD while maintaining visual acuity… we believe that our team has optimized the trial design to efficiently provide the necessary data to design the Phase 3 program. ODYSSEY will enroll treatment-experienced participants with wet AMD and use aflibercept, a current standard of care, as the comparator, over 36 weeks of treatment. We expect ODYSSEY topline results in Q3 2024," concluded Dr. Lasezkay